| INTRODUC TI ON
Following solid organ transplantation, tacrolimus-based immunosuppression is the most commonly used treatment regimen to prevent allograft rejection. 1 As tacrolimus has a narrow therapeutic index, it is important that exposure to the drug is maintained within a tightly defined range, as overexposure can cause drug-related adverse effects and toxicity, 2 while underexposure is associated with poor transplant outcomes. 3, 4 Oral bioavailability of tacrolimus exhibits large interpatient variability 5 and, therefore, the dose of tacrolimus is optimized on the basis of maintaining the patients' systemic exposure within a narrow range. As the AUC for tacrolimus is significantly associated with efficacy, 2, 6 therapy is optimized on an individual patient basis by monitoring tacrolimus trough concentrations as a surrogate marker of AUC.
Available formulations of tacrolimus include twice-daily, immediate-release capsules and once-daily, prolonged-release capsules.
While immediate-release tacrolimus is approved for the prophylaxis of transplant rejection in adult and pediatric liver, kidney, and heart allograft recipients, 7 the prolonged-release formulation is approved for the prophylaxis of transplant rejection in adult liver and kidney allograft recipients only. Evidence suggests that converting patients from immediate-to prolonged-release tacrolimus maintenance immunosuppression can increase treatment adherence and reduce intrapatient variability in tacrolimus exposure, [8] [9] [10] which could potentially improve long-term transplant outcomes.
3,11
Extensive clinical experience suggests that stable adult transplant recipients can be safely converted from immediate-to prolonged-release tacrolimus on a 1 mg:1 mg total daily dose basis.
12-15
However, after conversion, trough concentrations of tacrolimus should be monitored, and the dose adjusted as required to ensure that adequate exposure to tacrolimus is maintained.
Currently, clinical experience with prolonged-release tacrolimus in pediatric patients is limited. In the pediatric studies reported to date, patients were converted on a 1 mg:1 mg basis. Heffron et al reported data from a study performed in 18 stable pediatric liver transplant patients, which suggested that the mean exposure to tacrolimus over 24 hours (AUC 24 ) was similar between prolonged-and immediate-release tacrolimus. 16 Min et al reported data from 34
Korean pediatric renal transplant patients and showed that AUC 24 7 days after conversion was approximately 15% lower with prolonged-vs immediate-release tacrolimus. 17 However, following dose adjustments during a further 2-week period, tacrolimus exposure was similar between the formulations, with a comparable mean overall dose. 17 Additionally, in a study by Lapeyraque et al, data from 19 pediatric kidney transplant patients suggested that the median tacrolimus AUC 24 was approximately 10% lower with the prolonged-release vs the immediate-release formulation. 18 However, these were smallscale studies and warrant further research to confirm that stable pediatric transplant recipients can be safely converted from immediate-release to prolonged-release tacrolimus at the same total daily dose. We therefore undertook the current larger study to compare the PK of tacrolimus before and after conversion from immediateto prolonged-release tacrolimus in stable pediatric kidney, liver, and heart allograft recipients. and between PR-T and IR-T (rho 0.89 and 0.84, respectively), suggesting that stable pediatric transplant recipients can be converted from IR-T to PR-T at the same total daily dose, using the same therapeutic drug monitoring method.
| PATIENTS AND ME THODS

| Study design
K E Y W O R D S
heart transplantation, kidney transplantation, liver transplantation, pediatrics, pharmacokinetics, tacrolimus center approved the study protocol. Prior to study commencement, written informed consent was obtained from all individual participants included in the study (if appropriately aged to provide consent) or their guardian. Patients could withdraw from the study at any time.
| Patients
Patients were included if they were aged ≥5 and ≤16 years, able to swallow intact drug capsules, had received a heart, liver, or kidney transplant ≥6 months before the study, were maintained on an immediate-release tacrolimus-based immunosuppressive regimen for ≥3 months, and were clinically stable in the opinion of the investigator. Patients included were required to have had stable whole-blood tacrolimus trough levels between 3.5 and 15.0 ng/mL, measured on at least two separate occasions, ≥6 days apart, and within 30 days of study commencement.
Key exclusion criteria were multiple organ transplantation, and any rejection episode either <3 months before the study, or <6 months before the study if antibody therapy was required.
Patients could not be receiving sirolimus, everolimus, or formulations of mycophenolic acid (other than MMF). While generic formulations of MMF were not excluded, they were not used by any of the participating centers. Patients were also excluded if they required treatment with medications known to inhibit or induce tacrolimus metabolism during, or within 28 days prior to, the study. Patients could continue to receive steroids, azathioprine, or MMF throughout the study period, at constant dose, if they had been taking these treatments before enrollment.
| Study treatment
| Pharmacokinetic profiles assessment
For the PK analysis, the first blood sample was taken after a fasting period of at least 6 hours, before study drug administration. 12 The betweenday and within-day precision of the assay at concentrations of 0.3, 4.0, and 8.0 ng/mL was <5.0% coefficient of variation. 19 All procedures were performed in compliance with the principles of Good Laboratory Practice.
The primary end-point was the AUC 24 of tacrolimus on Days 7 and 14. Secondary end-points were maximum tacrolimus concentration (C max ), time to C max (T max ), and tacrolimus C 24 , on Days 7 and 14.
Other end-points included tacrolimus dose and trough levels, and the proportion of patients within the recommended whole-blood tacrolimus trough range (3.5-15.0 ng/mL) on Days 7 and 14.
| Statistical analyses and sample size calculation
Sample size was calculated using a significance level of p = 0.05, assuming a steady-state AUC 24 ratio of geometric LSM of 0.9, and a SD; log scale of 0.18, irrespective of the organ transplanted and age group. Using these parameters, 72 patients with two complete PK profiles provided 97% power to assess similarity of exposure. This was based on a two-sided 90% CI for the ratio of geometric LSM, and a similarity interval of 80%-125%.
The PKAS included all patients who received at least one dose of study medication and provided two complete PK profiles. Analyses were stratified by treatment and transplanted organ type (kidney, liver, or heart). To estimate the PK parameters, standard non-compartmental methods were used. AUC 24 was calculated using the linear-log trapezoidal rule. AUC 24 , C max , and C 24 were compared between prolonged-and immediate-release formulations using a mixed-effects model on log-transformed PK parameters, with treatment and organ transplanted included as fixed effects, age at baseline as a continuous covariate, and patient as a random effect. The difference of LSM of logtransformed PK parameters between formulations, and its 90% CI, was back-transformed to the raw scale and was expressed as percentages.
If the 90% CI for the ratio of geometric LSM was within the predefined similarity interval of 80%-125%, then the PK parameter was considered to be similar between tacrolimus formulations. Treatment-by-age and treatment-by-organ-transplant interactions were assessed for PK parameters using a mixed-effects model, with interactions deemed significant at an associated p value ≤0.10.
For both treatments, the correlation between C 24 and AUC 24 was assessed using regression analysis, and by calculating the Pearson correlation coefficient (rho). The correlation was classified as "strong" if it was greater than 0.7, and "moderate" if between 0.3 and 0.7 inclusive; below 0.3, the correlation was deemed "weak." SAS ® Version 9.3 or higher was used for all data processing, summarization, and analyses.
| RE SULTS
| Study population
Of 113 screened patients, 81 were enrolled and received study medication, of whom 74 (kidney, n = 45; liver, n = 28; heart, n = 1) were included in the PKAS (Figure 1 ). Patient baseline demographics and characteristics are presented in Table 1 ; due to the small patient numbers, statistical comparisons between organ types were not performed.
In the overall PKAS, over half of patients (59.5%) were male, and the mean ± SD age was 11.5 ± 2.8 years (range 5-16 years). Overall, 43.2% of patients were children (aged ≥5 to ≤11 years) and 56.8% were adolescents (aged ≥12 to ≤16 years). The mean ± SD height and weight were 144.4 ± 17.8 cm and 41.8 ± 15.6 kg, respectively, but there was wide variation, due to the age range of the patients.
| Dosage and trough levels
As per protocol, patients included in the PKAS did not have dose adjustments, and all were converted from immediate-to prolonged-release tacrolimus on a 1 mg:1 mg total daily dose basis.
Therefore, the mean ± SD tacrolimus daily dose (mg) was the same with immediate-release tacrolimus on Day 7 and prolonged-release tacrolimus on Day 14 (7.99 ± 4.94, 8.67 ± 5.66, 6.96 ± 3.42, and 6.00
(no SD) overall, and for kidney, liver, and heart recipients, respectively). The mean ± SD weight-adjusted tacrolimus daily doses (mg/ kg) were also similar with immediate-and prolonged-release tacrolimus on Days 7 and 14, respectively, for the overall PKAS, and by organ transplanted (Figure 2A ).
The mean ± SD tacrolimus trough levels were slightly lower with prolonged-release tacrolimus on Day 14 compared with immediaterelease tacrolimus on Day 7 ( Figure 2B ). Mean tacrolimus trough levels were approximately 20% lower in liver than in kidney recipients, irrespective of tacrolimus formulation. As data are available for only one patient, the higher tacrolimus trough level observed in the heart recipient (8. 
| Tacrolimus blood concentration-time profile
The mean whole-blood concentration-time curve of tacrolimus for the 24 hours after administration of the two formulations is presented for the overall PKAS in Figure 3 . As the immediate-release formulation is administered twice daily, the concentrationtime profile was biphasic, with a second concentration peak at approximately 14 hours, which was about 2 hours after the second dose.
| Pharmacokinetic parameters
Overall, the tacrolimus AUC 24 was comparable for prolonged-and immediate-release formulations (169.5 and 175.4 ng·h/mL, respectively). The geometric LSM ratio for prolonged-release:immediaterelease tacrolimus was 96.7%, and the 90% CI (92.3%, 101.2%) was within the predefined similarity interval ( Table 2) . As expected based on clinical practice, the mean exposure was higher in kidney than in liver transplant patients (p = 0.026). Nevertheless, tacrolimus systemic exposure was similar between formulations in both kidney and liver recipients (geometric LSM ratios (90% CI): 91.8%
(86.6%, 97.2%) and 104.1% (96.8%, 111.9%), respectively). As only one heart recipient was included in the PKAS, statistical assessment regarding the similarity of tacrolimus formulations was precluded for this organ type.
The 90% CIs of the geometric LSM ratio for C 24 were within the similarity interval for the overall PKAS, and when stratified by the organ transplanted (kidney or liver). Geometric LSM ratios for pro- Table 2) . No interaction was observed between treatment and transplanted organ for tacrolimus C 24 (p = 0.929).
With both the prolonged-release and immediate-release formulations, the linear relationships between tacrolimus AUC 24 and C 24 were similar, with a strong positive correlation (Figure 4 ), irrespective of organ type. For the overall population, the Pearson correlation coefficients were comparable with prolonged-and immediate-release tacrolimus (0.89 and 0.84, respectively). This was also true for kidney (0.89 and 0.90, respectively) and liver recipients (0.83 and 0.77).
In the overall population, the geometric LSM for C max was approximately 11 ng/mL with both formulations. The prolonged-release:immediate-release tacrolimus geometric LSM ratio (90% CI) was 94% (87.1%, 100.8%), and the 90% CI was within the predefined similarity interval (Table 2) . When stratified by organ transplant, the C max geometric LSM ratio 90% CI was within the predefined similarity interval for liver recipients, but the lower limit fell outside the range for Note. due to rounding errors, percentages may not add up to 100%. a SD and median are not reported for heart transplant, as n = 1. PKAS, pharmacokinetics analysis set;
SD, standard deviation.
TA B L E 1 Patient baseline demographics and characteristics for the overall population and stratified by organ type (PKAS) kidney transplant patients (Table 2 ). There was a significant interaction between treatment and organ transplanted, indicating that C max differed between recipients of different organs (p = 0.003).
Overall, mean T max was numerically longer with prolonged-vs immediate-release tacrolimus (mean ± SD 2.9 ± 3.6 vs 1.7 ± 1.1 hours, respectively). A similar pattern was observed in kidney and liver allograft recipients (Table 3 ).
| D ISCUSS I ON
While PK studies of stable pediatric patients converted from immediate-to prolonged-release tacrolimus have been published, [16] [17] [18] to our knowledge, this is the largest and most robust study to date. The study was designed to have a power of 97% to assess similarity of tacrolimus exposure between the formulations, based on a two-sided 90% CI for the ratio of geometric LSM and a similarity interval of 80%-125%. We report that, in a population of stable pediatric kidney, liver, and heart transplant patients converted from immediate-to prolonged-release tacrolimus (1 mg:1 mg), the mean systemic exposure to tacrolimus in pediatric liver transplant patients. 16 Targeting the same trough levels with both formulations should, therefore, provide comparable steady-state exposure to tacrolimus in stable pediatric transplant patients, converted from immediate-to prolonged-release tacrolimus on a 1 mg:1 mg total daily dose basis. Importantly, these data also suggest that the same therapeutic drug monitoring approach can be used with both formulations.
The observed mean C max was similar with both tacrolimus formulations in the overall PKAS and in the liver recipients in this study.
For AUC 24 and C max , we observed a significant interaction between treatment and transplanted organ type. The significance of these interactions is uncertain. Many factors may contribute to a difference in exposure between immediate-and prolonged-release tacrolimus, including age, concomitant medications, and genotype (e.g, cytochrome P450 3A5 polymorphisms). 20,21 However, as described above, the relationship between C 24 and AUC 24 is similar for both formulations; therefore, the same trough levels can be targeted.
We also observed that the mean T max was longer in patients receiving prolonged-release tacrolimus than in those receiving the immediate-release formulation (3 hours vs 2 hours, respectively), irrespective of transplanted organ type. This was expected, as the F I G U R E 3 Mean whole-blood concentration of tacrolimus for the overall PKAS (linear plot). n = 73 at 13, 14, and 18 h after prolonged-release tacrolimus administration, and at 1 and 13 h after immediate-release tacrolimus administration as the sample was not taken. The missing sample was not considered to affect the estimation of PK data. PK, pharmacokinetics; PKAS, pharmacokinetics analysis set; SD, standard deviation prolonged-release formulation has an extended oral absorption profile for tacrolimus, throughout the gastrointestinal tract, compared with the immediate-release formulation of tacrolimus.
22,23
Consistent with the study design, the mean daily dose (mg/kg) of tacrolimus was similar pre-and post-conversion from immediateto prolonged-release tacrolimus. Systemic exposure to tacrolimus was numerically higher in kidney recipients than in liver recipients.
This is not surprising as, in clinical practice, liver transplant patients tend to be maintained with lower exposure than kidney transplant recipients. In the overall PKAS, exposure to tacrolimus was slightly lower following prolonged-release tacrolimus administration (as indicated by prolonged-release:immediate-release tacrolimus geometric LSM ratios of 90.39% for AUC 24 and 96.66% for C 24 ); this has been observed in previous studies in adult transplant patients.
Across five studies of stable adult patients converted from immediate-to prolonged-release tacrolimus, the mean systemic exposure to tacrolimus (AUC 24 ) for the prolonged-release formulation was approximately 10% lower (mean from 3% to 13%) than that for immediate-release tacrolimus. 8, [12] [13] [14] [15] A recent head-to-head PK study found that a conversion factor of +8% was required to obtain similar tacrolimus exposure, when converting stable kidney transplant patients from immediate-to prolonged-release tacrolimus. 24 Note. SD and median are not reported for heart transplant, as n = 1. PKAS, pharmacokinetics analysis set; SD, standard deviation; T max , time to maximum concentration.
TA B L E 3 T max with prolonged-and immediate-release tacrolimus for the overall population and stratified by organ type (PKAS) and kidney recipients, no cases of biopsy-confirmed acute rejection, graft losses, or patient deaths were reported up to 1 year after conversion from immediate-to prolonged-release tacrolimus. 16, 25, 26 In this study, only pediatric patients aged ≥5 years were included, as participants needed to be capable of swallowing intact capsules.
Given that tacrolimus clearance is reportedly higher in children aged <5 years, 27 a once-daily formulation would not be appropriate in pediatric patients <5 years old. The results of this study are, therefore, not applicable to younger patients.
In conclusion, we report data from the largest PK study of pediatric solid organ recipients converted from immediate-to prolonged-release tacrolimus. Compared with other PK trials to date in this patient population, our study has the greatest statistical power to assess similarity of tacrolimus exposure between immediate-and prolonged-release formulations. In this study, AUC 24 and C 24 were within the predefined similarity intervals for these formulations, and the C 24 :AUC 24 relationship was similar between prolonged-and immediate-release tacrolimus. This indicates that targeting the same trough levels should provide comparable steady-state tacrolimus exposure, in pediatric solid organ recipients converted from twicedaily, immediate-release to once-daily, prolonged-release tacrolimus on a 1 mg:1 mg total daily dose basis. The same therapeutic drug monitoring approach may be used with both formulations.
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